@IntensityInc

Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to create safer and more efficacious cancer therapies. Nasdaq: $INTS

 Shelton, CT
intensitytherapeutics.com
Joined February 2013
  • Tweets764
  • Following258
  • Followers955
175Media
On the ground ftom @myESMO's 2026 conference in Madrid! $INTS' CEO Lew Bender is pictured alongside the presented poster highlighting early findings from the INVINCIBLE-4-SAKK 66/22 trial evaluating #INT2306 in early-stage #TNBC. #ESMO26
1
5
187
New INVINCIBLE4 data is coming to  @‌myESMO's 2026 conference! $INTS reported encouraging early results from the first 7 patients in Cohort A, including pCR in the breast and affected lymph nodes in 5 of 7 patients. The ePoster will be available beginning Oct. 23. 🔗: bit.ly/4iAkspz #ESMO26
1
2
12
349
What is pathological complete response, or pCR? pCR measures the absence of residual invasive cancer following neoadjuvant treatment at the time of surgery and is an important endpoint in breast cancer research. It is also an endpoint in our Phase 2 INVINCIBLE-4 study of INT230-6 in presurgical TNBC. Learn more about our clinical programs: intensitytherapeutics.com/cl… #BreastCancerAwarenessMonth
8
238
Progress is built study by study. In July 2026, the Company restarted patient treatment in the INVINCIBLE-4 Study. This is Phase 2 open-label, randomized controlled, multicenter study to analyze the clinical activity, safety, and tolerability of INT230-6 given before SOC in patients with early-stage, operable TNBC #BreastCancerAwarenessMonth
1
13
323
Why has intratumoral cancer treatment remained so challenging? In a new byline for Drug Delivery Leader, Intensity Therapeutics Founder and CEO Lew Bender explores the history of intratumoral cancer therapies, the scientific barriers that have limited their success, and why novel drug formulations may help move the field forward. Read Lew's full perspective in Drug Delivery Leader: bit.ly/3VMnSNf

Intratumoral Treatment Of Cancer: After Many Prior Attempts, Has The Time Finally Come?

Several companies are in Phase 3 development of intratumoral drug products, all with a lead product in a cancer other than melanoma, based on novel chemistry.

drugdeliveryleader.com
14
442
The pink suit has been busy this year. 💗 From @Runway4Recovery to presenting at #SABCS25, our CEO Lewis H. Bender has proudly worn pink in support of the breast cancer community. This #BreastCancerAwarenessMonth, the pink suit is back. $INTS
Intensity Therapeutics CEO, Lew Bender in a pink suit stands in front of a backdrop featuring the "Runway for Recovery" logo. In support of Breast Cancer Awareness Month.

ALT Intensity Therapeutics CEO, Lew Bender in a pink suit stands in front of a backdrop featuring the "Runway for Recovery" logo. In support of Breast Cancer Awareness Month.

Intensity Therapeutics CEO, Lew Bender in a pink suit stands in front of a backdrop featuring The San Antonio Breast Cancer Symposium. In support of Breast Cancer Awareness Month.

ALT Intensity Therapeutics CEO, Lew Bender in a pink suit stands in front of a backdrop featuring The San Antonio Breast Cancer Symposium. In support of Breast Cancer Awareness Month.

8
326
What if treating a tumor before surgery could do more than shrink it? Our Phase 2 INVINCIBLE-4 study is evaluating intratumoral INT230-6 followed by standard-of-care immunochemotherapy in presurgical TNBC. Learn More: intensitytherapeutics.com/te… Advancing the science this #BreastCancerAwarenessMonth. $INTS
A person is undergoing a mammogram in a medical facility. Text on the image highlights the Invincible-4 study by Intensity Therapeutics, focusing on advancing research in triple-negative breast cancer, evaluating INT230-6 in presurgical TNBC.

ALT A person is undergoing a mammogram in a medical facility. Text on the image highlights the Invincible-4 study by Intensity Therapeutics, focusing on advancing research in triple-negative breast cancer, evaluating INT230-6 in presurgical TNBC.

13
322
We're honored to share that Intensity Therapeutics has been shortlisted for Excellence in Oncology at the 2026 @Citeline Biotech Awards! Proud of our team's work advancing cancer research. 🔗 View the full shortlist: citeline.com/en/awards/citel… @Nasdaq: $INTS
1
11
466
What if we could rethink how chemotherapy is delivered to solid tumors? CEO Lewis H. Bender joins Dr. Moira Gunn on @biotechnation to discuss Intensity’s approach to delivering treatment directly into tumors and the thinking behind reengineering how we treat solid cancers. 🎧 Listen to the interview: biotechnation.com/episodes/r… $INTS
1
10
364
From a personal journey with breast cancer to the big screen. 🎬💗 This #BreastCancerAwarenessMonth, we’re proud to celebrate our collaborator and breast cancer survivor @handychristine1 as Hello Beautiful, inspired by her bestselling novel Walk Beside Me, arrives in theaters. We’re honored to stand beside Christine in helping bring greater awareness, education and hope to women facing breast cancer. Congratulations, Christine!
Lew Bender and former Victoria's Secret model and Breast Cancer Survivor Christine Handy stand in front of a scientific poster presentation at a conference. Both are holding certificates and smiling. They are on a carpeted floor in a large indoor venue with visible lighting fixtures above.

ALT Lew Bender and former Victoria's Secret model and Breast Cancer Survivor Christine Handy stand in front of a scientific poster presentation at a conference. Both are holding certificates and smiling. They are on a carpeted floor in a large indoor venue with visible lighting fixtures above.

1
1
16
391
This October, we’re thinking pink🎗💗 For #BreastCancerAwarenessMonth, we’re recognizing the patients, families, advocates & researchers driving progress while continuing our own work in TNBC through the Phase 2 INVINCIBLE-4 study. More to come! $INTS
Breast Cancer Awareness Month poster featuring a large pink ribbon design and the Intensity Therapeutics logo at the bottom.

ALT Breast Cancer Awareness Month poster featuring a large pink ribbon design and the Intensity Therapeutics logo at the bottom.

1
9
470
CEO Lewis H. Bender joins Jim Cornall on Base to Base Podcast to talk INT230-6, intratumoral treatment and Intensity’s approach to killing cancer cells while stimulating an immune response. 🎧 Intensity’s conversation starts around the 29-minute mark: deeptechdigest.com/biotech/b… $INTS
3
14
658
18 issued patents. 42 countries. 🌎 Our proprietary DfuseRx℠ technology is central to $INTS' approach to intratumoral cancer therapy and the development of INT230-6. Explore the science and IP behind our late-stage clinical programs: bit.ly/3T27pUh
The image features a promotional graphic from Intensity Therapeutics. It includes the phrases "Proprietary Science. Global Protection." and highlights "18 Issued Patents" and "42 Countries" on a green gradient background.

ALT The image features a promotional graphic from Intensity Therapeutics. It includes the phrases "Proprietary Science. Global Protection." and highlights "18 Issued Patents" and "42 Countries" on a green gradient background.

1
1
17
861
Our investigational INT230-6 is designed to kill tumors directly while stimulating a systemic anti-cancer immune response. With two late-stage clinical programs underway, we’re advancing a novel approach to treating solid tumors. Learn more about our technology and clinical programs: intensitytherapeutics.com @Nasdaq: $INTS
The image features the text "A New Weapon in the War on Cancer" in bold white letters on a green gradient background with stylized green lines. The logo of Intensity Therapeutics appears at the bottom right.

ALT The image features the text "A New Weapon in the War on Cancer" in bold white letters on a green gradient background with stylized green lines. The logo of Intensity Therapeutics appears at the bottom right.

1
2
1
13
671
$INTS CEO Lew Bender caught up with Dr. Swayampakula Ramakanth, Managing Director of Equity Research at @HCWCO, during this week's conference in NYC. Great connecting with the investment community!
Lew Bender from Intensity Therapeutics and an analyst from H.C. Wainwright together at their conference in NYC.

ALT Lew Bender from Intensity Therapeutics and an analyst from H.C. Wainwright together at their conference in NYC.

2
17
768
Going to @HCWCO? So is Lew. $INTS President & CEO Lewis H. Bender will be available for 1:1 meetings Sept. 14–16 in NYC. Come talk INT230-6, our late-stage clinical programs and what’s ahead for Intensity. 🤝 Request a meeting: bit.ly/3gk8b7C
The image is a promotional graphic for H.C. Wainwright featuring a person in business attire. The text announces that the Intensity Therapeutics President and CEO will attend for one-on-one meetings from September 14-16, 2026. The Intensity Therapeutics logo is in the top right corner.

ALT The image is a promotional graphic for H.C. Wainwright featuring a person in business attire. The text announces that the Intensity Therapeutics President and CEO will attend for one-on-one meetings from September 14-16, 2026. The Intensity Therapeutics logo is in the top right corner.

1
1
12
698
Treat locally. Act globally. Think differently about cancer. That idea has shaped $INTS since its founding and continues to drive the development of INT230-6: an investigational intratumoral therapy designed to kill tumors locally while engaging the immune system. Learn more about Intensity and our approach: bit.ly/4o9KWzf
2
11
714
$INTS is heading to New York. President & CEO Lewis H. Bender will participate in the @HCWCO Global Investment Conference Sept. 14–16. Watch the presentation: bit.ly/4AaYCjw Request a meeting: bit.ly/3gk8b7C Learn More: bit.ly/4ij34WP
Press release announcement for Intensity Therapeutics' participation in the H.C. Wainwright 28th Annual Global Investment Conference. The date mentioned is September 11, 2026, and availability on-demand at 7:00 am ET.

ALT Press release announcement for Intensity Therapeutics' participation in the H.C. Wainwright 28th Annual Global Investment Conference. The date mentioned is September 11, 2026, and availability on-demand at 7:00 am ET.

2
15
637
Big challenges call for great collaborators. $INTS has worked with @Merck, @bmsnews, and the @theNCI to explore INT230-6, including combinations with checkpoint inhibitors and research into its immune effects. Learn more: bit.ly/4n6awnX
The image features the logos of Merck, the National Cancer Institute (NIH), and Bristol Myers Squibb, under the heading "Our Partners: Advancing cancer research through collaboration." The Intensity Therapeutics logo is in the bottom right corner.

ALT The image features the logos of Merck, the National Cancer Institute (NIH), and Bristol Myers Squibb, under the heading "Our Partners: Advancing cancer research through collaboration." The Intensity Therapeutics logo is in the bottom right corner.

3
2
13
842
200+ patients of clinical experience. Two late-stage programs moving the pipeline forward. $INTS is advancing INT230-6 through Phase 3 in advanced soft tissue sarcoma and Phase 2 in neoadjuvant TNBC.
The image features the Intensity Therapeutics logo in the top right corner. Text in bold green reads "200+ Patients enrolled in 2 completed clinical trials, 2 Late-Stage Programs," and additional green text states "Phase 3 Sarcoma + Phase 2 TNBC." The background has wavy, abstract yellow lines.

ALT The image features the Intensity Therapeutics logo in the top right corner. Text in bold green reads "200+ Patients enrolled in 2 completed clinical trials, 2 Late-Stage Programs," and additional green text states "Phase 3 Sarcoma + Phase 2 TNBC." The background has wavy, abstract yellow lines.

3
15
662
Load more